The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Atrovent 250 UDVs 250 micrograms/ 1ml Nebuliser Solution

Boehringer Ingelheim International GmbHPA0775/012/002

Main Information

Trade NameAtrovent 250 UDVs 250 micrograms/ 1ml Nebuliser Solution
Active SubstancesIpratropium bromide
Dosage FormNebuliser solution
Licence HolderBoehringer Ingelheim International GmbH
Licence NumberPA0775/012/002

Group Information

ATC CodeR03BB Anticholinergics
R03BB01 ipratropium bromide


License statusAuthorised
Licence Issued10/06/1996
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
« Back